首页> 外文期刊>Expert opinion on pharmacotherapy >The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular disease
【24h】

The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular disease

机译:The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular disease

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Patients with cardiovascular diseases (CVD) are at increased risk of hyperkalemia, particularly when treated with renin-angiotensin-aldosterone inhibitors (RAASIs). Because the occurrence or fear of hyperkalemia, RAASIs are frequently down-titrated or discontinued in patients with CVD, with consequent worse outcomes than patients who remain on maximum doses.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号